PARkinson's: From cellular mechanisms to potential therapeutics.
Pharmacol Ther
; 230: 107968, 2022 02.
Article
em En
| MEDLINE
| ID: mdl-34391789
ABSTRACT
Our understanding of the progression and mechanisms underlying the onset of Parkinson's disease (PD) has grown enormously in the past few decades. There is growing evidence suggesting that poly (ADP-ribose) polymerase 1 (PARP-1) hyperactivation is involved in various neurodegenerative disorders, including PD, and that poly (ADP-ribose) (PAR)-dependent cell death is responsible for neuronal loss. In this review, we discuss the contribution of PARP-1 and PAR in the pathological process of PD. We describe the potential pathways regulated by the enzyme, review clinically relevant PARP-1 inhibitors as potential disease-modifying therapeutics for PD, and outline important factors that need to be considered for repurposing PARP-1 inhibitors for use in PD.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doença de Parkinson
/
Doenças Neurodegenerativas
Limite:
Humans
Idioma:
En
Revista:
Pharmacol Ther
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos